Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618889 | 0.89 | MAPT (0.52) | MAPTCHRM1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL25307693 | 0.87 | MAPT (0.54) | MAPTCHRM1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21597933 | 0.84 | ALDH1A1 (0.50) | MAPTCHRM1ALDH1A1KMT2A | |
| SCHEMBL21597937 | 0.82 | CHRM1 (0.48) | CHRM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31288731 | 0.82 | CHRM1 (0.39) | MAPTCHRM1ALDH1A1 | |
| SCHEMBL21061885 | 0.81 | MAPT (0.50) | MAPTCHRM1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21061543 | 0.81 | MAPT (0.50) | MAPTCHRM1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21597906 | 0.81 | CHRM1 (0.49) | MAPTCHRM1 | |
| SCHEMBL22449320 | 0.80 | CHRM1 (0.40) | MAPTCHRM1NPC1RAB9AKMT2A | |
| SCHEMBL21597926 | 0.80 | CHRM1 (0.63) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585143-B | Bridging compounds as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| EP-3810614-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| WO-2019243851-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPT 1215/4885CHRM1 1/4885ALDH1A1 2016/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MAPT 1215/4885CHRM1 1/4885ALDH1A1 2016/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPT 1215/4885CHRM1 1/4885ALDH1A1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.